List of Excipients in Branded Drug EXCEDRIN

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Haleon US Holdings LLC	EXCEDRIN	acetaminophen, asprin, caffeine	0067-2035	BENZOIC ACID
Haleon US Holdings LLC	EXCEDRIN	acetaminophen, asprin, caffeine	0067-2035	CELLULOSE, MICROCRYSTALLINE
Haleon US Holdings LLC	EXCEDRIN	acetaminophen, asprin, caffeine	0067-2035	D&C YELLOW NO. 10

Excedrin Excipient Strategy, Formulation Patents, and Commercial Opportunities

Last updated: October 17, 2026

Excedrin is an over-the-counter analgesic brand built around acetaminophen, aspirin, and caffeine combinations. Its commercial position depends less on active-ingredient exclusivity than on brand recognition, approved labeling, dosage-form performance, manufacturing reliability, and retail differentiation. The strongest excipient opportunities are faster disintegration, improved swallowability, reduced gastrointestinal burden, color and coating differentiation, and platform formulations that support new Excedrin variants.

What active ingredients and excipients does Excedrin use?

Excedrin products differ by indication and active-ingredient combination. Excedrin Migraine and Excedrin Extra Strength generally contain acetaminophen, aspirin, and caffeine. Excedrin Tension Headache contains acetaminophen and caffeine without aspirin.

Product	Acetaminophen per unit	Aspirin per unit	Caffeine per unit	Typical labeled use
Excedrin Migraine caplet	250 mg	250 mg	65 mg	Temporary relief of migraine
Excedrin Extra Strength caplet	250 mg	250 mg	65 mg	Temporary relief of minor aches and pains
Excedrin Tension Headache caplet	500 mg	0 mg	65 mg	Temporary relief of tension headache

The active-ingredient quantities are based on FDA labeling for the relevant products. Formulations and package configurations can change, so commercial diligence should use the current product-specific label and Drug Facts panel.[1-3]

Common excipients reported for Excedrin tablets and caplets include:

• Microcrystalline cellulose as a diluent and compression aid.
• Povidone as a binder.
• Croscarmellose sodium, crospovidone, or sodium starch glycolate as disintegrants, depending on the product.
• Colloidal silicon dioxide as a glidant.
• Stearic acid as a lubricant.
• Hypromellose, talc, titanium dioxide, and colorants in film-coating systems.
• Sodium lauryl sulfate or other wetting agents in selected formulations.
• Sodium benzoate and other formulation-specific processing or preservative components.

The exact excipient list is product-specific. Excipients should not be treated as interchangeable because changes can affect dissolution, tablet hardness, coating appearance, stability, taste, and regulatory filing requirements.

How does the Excedrin formulation create commercial value?

Excedrin’s formulation value comes from combining three familiar analgesic ingredients in a single dosage form. Acetaminophen provides analgesic and antipyretic activity, aspirin provides analgesic activity and contributes an anti-inflammatory mechanism, and caffeine can enhance analgesic effects in some headache products.[4]

The commercial proposition is convenience and differentiated symptom positioning. The formulation also creates technical constraints:

1. Acetaminophen, aspirin, and caffeine have different particle properties, solubilities, and stability profiles.
2. Aspirin is vulnerable to hydrolysis, particularly under conditions of moisture exposure.
3. Caffeine can affect blend uniformity and dissolution behavior.
4. High active loading limits the amount of excipient available for flow, binding, and disintegration control.
5. Film coating must protect the tablet without delaying release.

An excipient strategy therefore needs to balance manufacturability with rapid drug release. A formulation that increases tablet hardness may reduce friability but slow disintegration. A more porous tablet may improve release but create packaging and breakage problems.

What excipient strategies could improve Excedrin?

Faster disintegration and onset of action

A migraine product competes partly on perceived speed. Direct-compression systems using optimized grades of microcrystalline cellulose, crospovidone, or croscarmellose sodium could improve liquid penetration and tablet breakup.

Commercially relevant development targets include:

• Reduced disintegration time without loss of mechanical strength.
• Consistent dissolution across manufacturing sites.
• Lower sensitivity to compression force.
• Better performance after exposure to humidity.
• Compatibility with high-speed tablet presses.

A faster-disintegrating caplet could support a legally compliant “fast-dissolving” or “rapid-release” positioning if supported by comparative performance data and permitted labeling.

Improved swallowability

Migraine patients may experience nausea, making large or rough tablets less acceptable. Opportunities include:

• Smaller tablet geometry through higher-density excipients.
• Smooth film coatings with lower friction.
• Oval or capsule-shaped caplets.
• Orally disintegrating or chewable formats.
• Powder-filled capsules or stick-pack products.

These approaches require careful taste management. Aspirin and caffeine can produce a bitter or acidic taste profile, while acetaminophen can create a persistent aftertaste. Sweeteners, flavors, coating polymers, ion-exchange resins, and taste-masking barriers can add value but also increase manufacturing complexity.

Gastrointestinal tolerability

Aspirin creates a commercial and medical limitation because of gastrointestinal irritation and bleeding risk. Excipients cannot eliminate aspirin’s pharmacologic risk, but formulation choices may reduce local tablet irritation or improve dispersion.

Potential approaches include:

• Faster dispersion to reduce localized high concentrations.
• Film-coated tablets.
• Multiparticulate systems.
• Buffered or effervescent formats, where permitted and clinically justified.
• Lower moisture exposure and controlled packaging.

Any claim that a formulation is gentler on the stomach would require appropriate substantiation and regulatory review. A buffering excipient also changes sodium content, dissolution, stability, and label requirements.

Moisture protection and aspirin stability

Aspirin hydrolysis produces salicylic acid and acetic acid. Moisture management is therefore central to manufacturing and shelf life.

Relevant excipient and packaging tactics include:

• Low-moisture excipient grades.
• Moisture-barrier film coatings.
• Desiccant-containing bottles.
• High-barrier blister packaging.
• Reduced water activity during granulation.
• In-process controls for residual moisture.
• Stability testing under accelerated and long-term conditions.

Packaging is part of the formulation strategy. A technically superior tablet can lose commercial value if it requires expensive packaging or has poor stability in consumer bathrooms and travel conditions.

What formulations are protected by Excedrin patents?

Excedrin’s core active combination is old and widely available through generic products. The main commercial protections are therefore brand, trade dress, product recognition, distribution, manufacturing know-how, and potentially formulation-specific intellectual property rather than a durable composition-of-matter patent.

A patent search should separate four categories:

IP category	Excedrin relevance	Commercial effect
Active-ingredient composition	Limited for the basic acetaminophen-aspirin-caffeine combination	Generic manufacturers can use the same actives
Tablet formulation	Potentially relevant for specific excipient ratios, coating systems, or release profiles	May create narrow design-around risk
Method of use	Potentially relevant only for particular indications or dosing claims	OTC label and monograph constraints limit scope
Brand and trade dress	High practical relevance	Supports shelf recognition and consumer substitution resistance

No current business decision should assume that an Excedrin formulation patent blocks generic competition without a claim-by-claim review of issued patents, prosecution history, terminal disclaimers, maintenance fees, and relevant jurisdictions.

What is the Orange Book status of Excedrin?

Excedrin is primarily an OTC product family. OTC products may be marketed under an FDA monograph pathway, an approved application, or a combination of regulatory routes depending on the specific product and history.

The Orange Book is most important for approved prescription and certain approved nonprescription drug applications. It is not the primary competitive framework for monograph-compliant OTC analgesics. A prospective competitor should review:

• The current FDA monograph for internal analgesic, antipyretic, and antirheumatic products.
• FDA Drug Facts labeling.
• Any product-specific NDA or ANDA records.
• FDA enforcement history.
• Patent listings, if any, in the relevant approved application.
• Trademark and trade-dress rights.

FDA’s OTC monograph framework defines permitted active ingredients, concentrations, indications, warnings, and directions. An excipient change that does not alter active ingredients may still require documentation, stability data, manufacturing controls, or an application if it moves the product outside the applicable monograph pathway.[5]

When does Excedrin lose exclusivity?

Excedrin does not have a single exclusivity expiration date comparable to a patented prescription drug. The core formulation has long been exposed to generic competition.

The effective exclusivity timeline is:

Protection	Status
Basic acetaminophen, aspirin, and caffeine combination	Generic and widely available
OTC monograph status	Available to compliant competitors
Excedrin trademark	Continues while maintained and used
Trade dress and packaging	May continue but can be challenged or designed around
Specific formulation patents	Must be assessed individually
Retail and distribution relationships	Commercially durable but not statutory exclusivity

Generic and private-label products can compete without copying Excedrin branding. The commercial barrier is consumer recognition, not active-ingredient exclusivity.

Which companies are challenging Excedrin?

Competition comes from multiple classes of manufacturers rather than a single Paragraph IV challenger.

Generic analgesic manufacturers

Private-label and generic manufacturers sell acetaminophen-aspirin-caffeine combinations, including products labeled for migraine or headache relief. These products can compete on price, count size, retailer placement, and store-brand loyalty.

Branded analgesic companies

Johnson & Johnson’s Tylenol competes primarily through acetaminophen products. Haleon’s Advil competes through ibuprofen products, including migraine-oriented products. Bayer and other manufacturers compete in aspirin and headache categories.

Retail pharmacy and private-label brands

Retailers can source equivalent active combinations from contract manufacturers. These products typically have lower marketing expense and can undercut branded Excedrin pricing.

New delivery-form competitors

Chewables, powders, liquid gels, effervescent products, orally disintegrating tablets, and rapid-release caplets create competitive pressure even when the active ingredients are similar.

How strong is the Excedrin patent estate?

The core Excedrin patent estate should be considered weak as a barrier to basic generic entry because the primary ingredients and conventional tablet formats are established technologies. The brand’s stronger assets are non-patent rights and execution capabilities.

Factor	Assessment
Composition-of-matter protection	Low
Basic tablet formulation protection	Low to moderate, depending on claim scope
New delivery system protection	Potentially moderate
Manufacturing know-how	Moderate
Trademark recognition	Strong
Consumer loyalty	Strong but price-sensitive
Regulatory barrier to equivalent OTC products	Low to moderate
Design-around difficulty	Generally low for conventional tablets

A novel excipient system could improve the estate. Examples include a moisture-resistant aspirin platform, a rapid-release multilayer tablet, a taste-masked orally disintegrating formulation, or a low-irritation multiparticulate system. Patent strength would depend on unexpected performance, narrow claim drafting, comparative data, and freedom to operate around existing excipient patents.

What generic launch risks exist for Excedrin?

A generic launch can occur through a conventional tablet or caplet with the same active ingredients and compliant labeling. The main risks are commercial rather than legal:

• Retailers may favor lower-cost private-label products.
• Consumers may substitute based on price.
• Pharmacy shelving can reduce branded visibility.
• Generic manufacturers may use larger count sizes.
• Online retailers can compare prices instantly.
• A generic may match the active ingredients while offering a more convenient dosage form.

Excedrin can defend share through differentiated packaging, rapid-release performance, migraine-specific consumer education, convenience formats, and reliable supply. Claims must remain within FDA requirements.

What licensing opportunities exist for Excedrin excipients and delivery systems?

Potential licensing targets include:

• Direct-compression excipient platforms that support high active loading.
• Low-moisture excipient systems for aspirin-containing tablets.
• Rapid-disintegration technologies.
• Taste-masking systems for chewable or orally disintegrating products.
• Film-coating technologies that improve swallowability.
• High-barrier blister and bottle systems.
• Continuous manufacturing or improved blend-uniformity processes.
• Excipient suppliers with regulatory files and global manufacturing capacity.

The most valuable deal structure would likely involve a platform license covering multiple OTC analgesic products rather than a single Excedrin SKU. A partner would need rights to the formulation, manufacturing process, analytical methods, stability package, and relevant regulatory support.

How does Excedrin compare with competing headache medicines?

Product category	Primary actives	Excipient opportunity	Main commercial advantage	Main limitation
Excedrin Migraine	Acetaminophen, aspirin, caffeine	Rapid release, coating, moisture protection	Combination analgesia and established brand	Aspirin-related warnings
Acetaminophen products	Acetaminophen	Small tablets, gels, liquids	Broad consumer familiarity	Dose-related liver toxicity risk
Ibuprofen migraine products	Ibuprofen	Liquid gels, rapid-release systems	Anti-inflammatory positioning	NSAID gastrointestinal and cardiovascular warnings
Aspirin products	Aspirin	Buffered and enteric systems	Low cost and familiarity	Gastrointestinal and bleeding risks
Combination generics	Usually same as Excedrin	Low-cost conventional tablets	Price	Lower brand recognition

The most credible excipient opportunity is not a simple copy of the existing tablet. It is a differentiated delivery system that improves user experience while preserving monograph compliance and low-cost manufacturing.

What FDA regulatory issues affect Excedrin reformulation?

Excipients are inactive, but they are not regulatory-neutral. A reformulation can affect:

• Identity and quantity of inactive ingredients.
• Dissolution and disintegration.
• Stability and impurity profiles.
• Tablet weight and appearance.
• Allergen and dietary labeling.
• Sodium, sugar, or colorant declarations.
• Bioequivalence or comparative performance requirements.
• Manufacturing controls and batch release specifications.

FDA’s Inactive Ingredient Database can help identify precedent for particular excipients and routes of administration, but prior use does not establish automatic acceptance for every concentration or dosage form.[6]

A reformulation that changes the active ingredients, labeled indication, dosing instructions, or monograph conditions may require a different regulatory pathway than a routine excipient change.

What is the commercial value of an Excedrin excipient platform?

The best opportunities fall into three tiers:

1. Near-term line extension: improved coating, smaller caplet, better bottle or blister, and a rapid-disintegration format.
2. Mid-term differentiation: chewable, orally disintegrating, or taste-masked product.
3. Higher-risk innovation: multiparticulate or buffered systems with new performance claims and a broader patent position.

The first tier offers the best balance of development cost, regulatory predictability, and retail feasibility. The third tier could create stronger intellectual property but would face greater stability, labeling, manufacturing, and clinical-substantiation requirements.

Key Takeaways

• Excedrin’s basic active-ingredient combination is generic and does not provide meaningful composition-of-matter exclusivity.
• The principal actives are acetaminophen, aspirin, and caffeine in Excedrin Migraine and Excedrin Extra Strength; Excedrin Tension Headache replaces aspirin with a higher acetaminophen dose.
• The highest-value excipient opportunities are rapid disintegration, improved swallowability, aspirin moisture protection, taste masking, and lower-complexity manufacturing.
• Excedrin’s commercial protection comes mainly from trademarks, brand recognition, retail execution, and consumer familiarity.
• OTC monograph compliance is more important than a conventional Orange Book and Paragraph IV strategy for many Excedrin competitors.
• A differentiated delivery system could produce stronger patent protection than a conventional tablet, but only with demonstrable technical advantages.
• Generic entry risk is high for standard tablets and lower for proprietary formats with meaningful consumer benefits.

FAQs

Can a generic use the same Excedrin excipients?

Yes. Generic manufacturers can use the same or different inactive ingredients if the product satisfies applicable FDA requirements, labeling conditions, manufacturing standards, and performance specifications.

Does caffeine improve Excedrin’s patent position?

No. Caffeine may support the product’s pharmacologic and commercial positioning, but its inclusion does not by itself create meaningful patent protection for an established analgesic combination.

Can an excipient change create a new patent?

Yes. A new patent may be available for a novel composition, excipient ratio, coating, process, or delivery system if it is novel, non-obvious, useful, and adequately supported by data. Conventional substitution of one disintegrant for another is less likely to support strong claims.

Is an effervescent Excedrin product commercially attractive?

It could be attractive because effervescence may improve dispersion and user experience. The format would require careful control of moisture, sodium content, stability, packaging, taste, and FDA labeling.

Does a reformulated Excedrin product receive new OTC exclusivity?

Usually not automatically. A new formulation may obtain patent protection or application-specific regulatory rights, but an excipient change alone does not create the type of statutory market exclusivity associated with a newly approved prescription drug.

References

1. U.S. Food and Drug Administration. (n.d.). Excedrin Migraine: Drug facts label. DailyMed.

2. U.S. Food and Drug Administration. (n.d.). Excedrin Extra Strength: Drug facts label. DailyMed.

3. U.S. Food and Drug Administration. (n.d.). Excedrin Tension Headache: Drug facts label. DailyMed.

4. U.S. Food and Drug Administration. (2020). OTC monograph M013: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use. FDA.

5. Electronic Code of Federal Regulations. (n.d.). 21 C.F.R. Part 343: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use.

6. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. FDA.